GlaxoSmithKline Stock News

British drugmaker GSK said on Monday its blood cancer drug Blenrep, when used as a second-line treatment, had met its primary goal of progression free survival in a late-stage trial.

Cameroon received its first shipment of Mosquirix malaria vaccines manufactured by British drugmaker GSK Plc late on Tuesday, as the nation struggles with the mosquito-borne disease that kills more th

Without rehashing the wild ride we experienced in the market the last couple of months with triple digit gains and losses, I could find comfort in one thing, my dividends. Dividends may not increase e

GSK PLC (LSE:GSK, NYSE:GSK) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its drug, momelotinib, a treatment for

British drugmaker GSK on Monday said the human medicines committee of the European Medicines Agency had recommended approving its oral therapy to treat anaemia in patients with a type of bone marrow c

Arexvy, GSK's recently launched respiratory syncytial virus (RSV) vaccine, has made a strong start but management remained cautious given the recent launch and broker Berenberg says this is understand

GSK NYSE: GSK is not immune to the patent cliff faced by the pharmaceutical industry, but it is about as well prepared as it can be. The company faces a smaller impact than others, has years to go bef

A record number of Americans are now turning 65, Forbes recently reported, amid tens of millions of Baby Boomers. In fact, according to one report, 76.4 million Baby Boomers are living in America curr

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

GSK PLC (LSE:GSK, NYSE:GSK)'s seemingly positive earnings release on Wednesday has been labelled as just that by Stifel analysts, who were left mulling reasons for a subsequent drop in its share price

For conservative investors, including those in and nearing retirement, highly reliable dividend stocks with a growth component are an excellent tool. That's because these equities produce regular inco

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on the back of strong RSV vaccine sales.

GSK PLC (LSE:GSK, NYSE:GSK) has received mixed reactions from City analysts despite an objectively strong third-quarter performance and raised financial guidance. Shore Capital Markets praise the “s

GSK (GSK) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.09 per share a year ago.

High demand for the vaccine pulled in around $850 million during the third quarter—reportedly double what analysts were expecting—and GSK said annual sales could top $1 billion.